guest ::
| Home > Publications database > Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas. > print |
| Home > Publications database > Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas. > print |
| 001 | 142027 | ||
| 005 | 20240229105139.0 | ||
| 024 | 7 | _ | |a 10.1097/CCO.0000000000000478 |2 doi |
| 024 | 7 | _ | |a pmid:30102604 |2 pmid |
| 024 | 7 | _ | |a 1040-8738 |2 ISSN |
| 024 | 7 | _ | |a 1040-8746 |2 ISSN |
| 024 | 7 | _ | |a 1531-7021 |2 ISSN |
| 024 | 7 | _ | |a 1531-703X |2 ISSN |
| 024 | 7 | _ | |a altmetric:46501673 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2018-02257 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Friedrich, Mirco |0 P:(DE-He78)1cab354af0aff62f1b8d569477b4be4c |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas. |
| 260 | _ | _ | |a [S.l.] |c 2018 |b Ovid |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1659697606_13807 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The present review introduces recent progress in eliciting the role of mutant isocitrate dehydrogenase (IDH) in gliomas, especially regarding its mode of action as a modulator of antitumor immune response, and provides rationales for targeting mutant IDH in glioma immunotherapy. Both the development of small molecule inhibitors repressing the enzymatic activity of mutant IDH and novel, mechanism-led combination immunotherapies are discussed.Since the discovery of highly frequent IDH mutations in low-grade gliomas and nonsolid malignancies, its tumor cell-intrinsic effects have been intensively investigated. Tumor cells expressing mutant IDH display profound alterations of redox control capacity, phospholipid profile, and ATP supply. Recent findings suggest that IDH mutations - via intricate, yet druggable pathways - cause immunological alterations, highlighting the importance of oncogenic drivers as modulators of antitumor immunity and targets for immunotherapy.Mutant IDH is not only a disease-defining biomarker and oncogenic driver in glioma, but is also a neoantigen and a regulator of glioma immune evasion. Effective and specific strategies targeting the immunomodulatory properties of mutant IDH may complement current (immuno-)therapeutic strategies and approved antiglioma treatments to improve outcome. |
| 536 | _ | _ | |a 317 - Translational cancer research (POF3-317) |0 G:(DE-HGF)POF3-317 |c POF3-317 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Bunse, Lukas |0 P:(DE-He78)e579130c57e8c686ed1c2dedfa595985 |b 1 |u dkfz |
| 700 | 1 | _ | |a Wick, Wolfgang |0 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee |b 2 |u dkfz |
| 700 | 1 | _ | |a Platten, Michael |0 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5 |b 3 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1097/CCO.0000000000000478 |g Vol. 30, no. 6, p. 1 - |0 PERI:(DE-600)2026986-9 |n 6 |p 368-374 |t Current opinion in oncology |v 30 |y 2018 |x 1040-8746 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:142027 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)1cab354af0aff62f1b8d569477b4be4c |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)e579130c57e8c686ed1c2dedfa595985 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-317 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Translational cancer research |x 0 |
| 914 | 1 | _ | |y 2018 |
| 915 | _ | _ | |a Allianz-Lizenz |0 StatID:(DE-HGF)0410 |2 StatID |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CURR OPIN ONCOL : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1120 |2 StatID |b BIOSIS Reviews Reports And Meetings |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-He78)G160-20160331 |k G160 |l Neuroimmunologie und Hirntumorimmunologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)G370-20160331 |k G370 |l KKE Neuroonkologie |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)L101-20160331 |k L101 |l DKTK Heidelberg |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)G160-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G370-20160331 |
| 980 | _ | _ | |a I:(DE-He78)L101-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|